Monica Xu
About Monica
Monica focuses on representing high-growth emerging companies, as well as venture capital and other investors, on cross-border transactions in different industries across Asia, the US and worldwide. Her practice includes various stages of venture capital and private equity financings, mergers and acquisitions, formations and restructurings, joint ventures, spinoffs, foreign direct investments, outbound investments, research and license collaborations, employee equity incentives, corporate governance matters, manufacturing and distribution arrangements, other corporate and strategic transactions, and general corporate matters. Monica counsels companies from startups to well-established organizations in industries including life sciences, biotechnology, healthcare, medical devices, technology, media, telecom, high tech, fintech, ecommerce, edtech, software, digital health and many others.
Before joining Cooley, Monica worked at a leading law firm in China. She is a registered attorney in New York and is qualified to practice law in the People’s Republic of China (PRC).
Monica is a native Mandarin speaker and is fluent in English.
Monica was listed in Asia Legal Business’ China Top 15 Female Lawyers (2025), recognized as a Key Lawyer for Life Sciences and Healthcare, Private Equity and Venture Capital Foreign Firm (2025) in The Legal 500 Greater China rankings, and shortlisted in the IFLR Asia-Pacific as a Rising Star: International Firm (2025).
Passions
Reading
Tennis
Hiking
Dance
I am passionate about supporting emerging companies and investors in cross-border transactions with my experience and practical business judgment.
Key stats on Monica
-
800+
private financings completed for clients globally
-
1st
and afterwards investments in the PRC completed for many fund clients
-
Founding member of Cooley’s Shanghai office and the longest-serving attorney among Cooley Asia offices
Experience
-
Inmagene Biopharmaceuticals Completes Merger With Ikena Oncology [UPDATED]
-
DualityBio Announces HK$1.64 Billion IPO
-
Chimagen Biosciences Announces Sale of CMG1A46 to GSK
-
Angitia Biopharmaceuticals Announces $120 Million Series C
-
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
Admissions and credentials
- New York
Rankings and accolades
Asian Legal Business: China Top 15 Female Lawyers (2025)
IFLR Asia-Pacific Awards: Shortlisted for Rising Star – International Firm (2025)
The Legal 500 Greater China: Key Lawyer for Life Sciences and Healthcare, Private Equity and Venture Capital – Foreign Firm (2025)
Get In Touch
Location
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.